Challenges With a Precision Medicine-Based Approach in Oncology

Holli Dilks, PhD
Published: Monday, Aug 01, 2016


Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.
 

Holli Dilks, PhD, director, Personalized Medicine Operations, Sarah Cannon Research Institute, discusses the challenges associated with having a precision medicine-based approach in the field of oncology.

One of the major challenges oncologists face is tissue availability in the field, Dilks explains. An exciting area of research that is aiming to guide this solution is liquid biopsies. Another obstacle is the ability to conduct a biopsy at the right time; tissue that is relevant to a patient's tumor is important.

Cost is an ongoing factor in precision medicine and the ability to afford such testing and personalized therapies is key, Dilks says. Additionally, resistance mutations that arise from targeted therapies is an issue that needs to be addressed.

Finally, education on the various alternations and how they can impact an individual patient's tumor is necessary, she adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x